Braveheart Bio

Braveheart Bio is a private, pre-revenue biotech company advancing BHB-1893, a selective cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM). The company is positioned in a competitive but high-need cardiovascular space, with its candidate designed for greater convenience and accessibility compared to existing therapies. Recent positive Phase 2 results from a partnership with Hengrui Pharma in China and a seasoned leadership team provide momentum as the program advances into late-stage trials. The company aims to address significant unmet needs in both obstructive and non-obstructive HCM.

Selective, reversible small-molecule cardiac myosin inhibition platform for reducing hypercontractility in heart muscle.

Braveheart competes in the cardiac myosin inhibitor space against Bristol Myers Squibb (Camzyos) and Cytokinetics (aficamten), which have first-mover advantage and commercial infrastructure. Competition is based on efficacy, safety, and particularly dosing convenience. The company aims to differentiate BHB-1893 through a potentially superior convenience profile.